For the twelve months ended Sep 30, 2026, Decoy Therapeutics Inc. reported -$16.56M of net income.
DCOY revenueQ3 2026$307.4K
- QoQ
- +35.1%
- FY YoY
- -100.0%
DCOY revenue was $307.4K in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier and up 35.1% from the prior quarter. For the full fiscal 2022 it was $0, down 100.0% from fiscal 2021.
DCOY net incomeQ3 2026-$2.99M
DCOY net income was -$2.99M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$873.5K a year earlier. For the full fiscal 2025 it was -$12.52M, compared with -$5.58M in fiscal 2024.
DCOY EPSQ3 2026-$3.53
DCOY diluted EPS was -$3.53 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$129.10, compared with -$69.54 in fiscal 2024.
DCOY free cash flowFY2025-$5.40M
DCOY free cash flow was -$5.40M for fiscal 2025 (ended Dec 31, 2025), compared with -$4.53M in fiscal 2024.
Source: XBRL data Decoy Therapeutics Inc. files with the SEC, latest filing dated Nov 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Nov 10, 2022; 1-for-8, first reported Aug 9, 2024; 1-for-15, first reported Nov 14, 2025; 1-for-12, first reported Mar 31, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.